Ofatumumab for the maintenance treatment of relapsed chronic lymphocytic leukaemia [ID732]
Discontinued
Reference number: GID-TAG482
As you will be aware, the Department of Health has asked us to conduct a Single Technology Appraisal of ofatumumab within its licensed indication for the maintenance treatment of relapsed chronic lymphocytic leukaemia.
However, the company have advised that they will not be pursuing a licensing application for ofatumumab from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal on its work programme.
As this appraisal has been referred to NICE we will continue to monitor any development and will update interested parties if the situation changes.